256 related articles for article (PubMed ID: 32758161)
1. HIV-associated neurocognitive disorder and HIV-associated myelopathy in a patient with a preserved CD4, but high viral load-a rarely reported phenomenon: a case report and literature review.
Ayele BA; Amogne W; Gemechu L
BMC Infect Dis; 2020 Aug; 20(1):574. PubMed ID: 32758161
[TBL] [Abstract][Full Text] [Related]
2. A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.
Vassallo M; Fabre R; Durant J; Lebrun-Frenay C; Joly H; Ticchioni M; DeSalvador F; Harvey-Langton A; Dunais B; Laffon M; Cottalorda J; Dellamonica P; Pradier C
J Neurovirol; 2017 Apr; 23(2):216-225. PubMed ID: 27815816
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients.
Rokx C; Schurink CA; Boucher CA; Rijnders BJ
J Antimicrob Chemother; 2016 Jun; 71(6):1632-6. PubMed ID: 26888910
[TBL] [Abstract][Full Text] [Related]
4. Changing clinical phenotypes of HIV-associated neurocognitive disorders.
Sacktor N
J Neurovirol; 2018 Apr; 24(2):141-145. PubMed ID: 28752495
[TBL] [Abstract][Full Text] [Related]
5. Neuropsychological Assessment of 412 HIV-Infected Individuals in São Paulo, Brazil.
Gascón MRP; Vidal JE; Mazzaro YM; Smid J; Marcusso RMN; Capitão CG; Coutinho EM; Benute GRG; De Lucia MCS; de Oliveira ACP
AIDS Patient Care STDS; 2018 Jan; 32(1):1-8. PubMed ID: 29323557
[TBL] [Abstract][Full Text] [Related]
6. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.
Todd S; Rafferty P; Walker E; Hunter M; Dinsmore WW; Donnelly CM; McCarty EJ; Quah SP; Emerson CR
Int J STD AIDS; 2017 Oct; 28(11):1074-1081. PubMed ID: 28118801
[TBL] [Abstract][Full Text] [Related]
7. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
Bogoch II; Davis BT; Venna N
J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
[TBL] [Abstract][Full Text] [Related]
8. Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy.
Castagna A; Rusconi S; Gulminetti R; Bonora S; Mazzola G; Quiros-Roldan ME; De Socio GV; Ladisa N; Carosella S; Cattelan A; Di Giambenedetto S; Mena M; Poli A; Galli L; Riva A;
AIDS; 2019 Jun; 33(7):1256-1260. PubMed ID: 30870194
[TBL] [Abstract][Full Text] [Related]
9. Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy.
Wijting I; Rutsaert SL; Rokx C; Burger DM; Verbon A; van Kampen J; Boucher C; Rijnders B; Vandekerckhove L
HIV Med; 2019 Jan; 20(1):63-68. PubMed ID: 30270543
[TBL] [Abstract][Full Text] [Related]
10. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
[TBL] [Abstract][Full Text] [Related]
11. HIV-Associated Vacuolar Myelopathy and HIV-Associated Dementia as the Initial Manifestation of HIV/AIDS.
Wuliji N; Mandell MJ; Lunt JM; Merando A
Case Rep Infect Dis; 2019; 2019():3842425. PubMed ID: 31637067
[TBL] [Abstract][Full Text] [Related]
12. [HIV-1 associated encephalopathy and myelopathy].
Eggers C
Nervenarzt; 2000 Aug; 71(8):677-84. PubMed ID: 10996920
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood lymphocyte HIV DNA levels correlate with HIV associated neurocognitive disorders in Nigeria.
Jumare J; Sunshine S; Ahmed H; El-Kamary SS; Magder L; Hungerford L; Burdo T; Eyzaguirre LM; Umlauf A; Cherner M; Abimiku A; Charurat M; Li JZ; Blattner WA; Royal W
J Neurovirol; 2017 Jun; 23(3):474-482. PubMed ID: 28243867
[TBL] [Abstract][Full Text] [Related]
14. Neurodevelopmental/neuroradiologic recovery of a child infected with HIV after treatment with combination antiretroviral therapy using the HIV-specific protease inhibitor ritonavir.
Tepper VJ; Farley JJ; Rothman MI; Houck DL; Davis KF; Collins-Jones TL; Wachtel RC
Pediatrics; 1998 Mar; 101(3):E7. PubMed ID: 9493492
[TBL] [Abstract][Full Text] [Related]
15. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.
Heaton RK; Franklin DR; Ellis RJ; McCutchan JA; Letendre SL; Leblanc S; Corkran SH; Duarte NA; Clifford DB; Woods SP; Collier AC; Marra CM; Morgello S; Mindt MR; Taylor MJ; Marcotte TD; Atkinson JH; Wolfson T; Gelman BB; McArthur JC; Simpson DM; Abramson I; Gamst A; Fennema-Notestine C; Jernigan TL; Wong J; Grant I; ;
J Neurovirol; 2011 Feb; 17(1):3-16. PubMed ID: 21174240
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load <100 000 copies/mL: a medium-term follow-up.
Lanzafame M; Nicolè S; Gibellini D; Lattuada E; Cucchetto G; Rigo F; Diani E; Concia E; Vento S
J Antimicrob Chemother; 2017 Jul; 72(7):2136-2138. PubMed ID: 28387810
[No Abstract] [Full Text] [Related]
17. Multidrug-resistant HIV viral rebound during early syphilis: a case report.
Giacomelli A; Micheli V; Cattaneo D; Mancon A; Gervasoni C
BMC Infect Dis; 2020 Apr; 20(1):273. PubMed ID: 32264923
[TBL] [Abstract][Full Text] [Related]
18. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.
Ellis RJ; Badiee J; Vaida F; Letendre S; Heaton RK; Clifford D; Collier AC; Gelman B; McArthur J; Morgello S; McCutchan JA; Grant I;
AIDS; 2011 Sep; 25(14):1747-51. PubMed ID: 21750419
[TBL] [Abstract][Full Text] [Related]
19. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.
Sánchez-Ramón S; Bellón JM; Resino S; Cantó-Nogués C; Gurbindo D; Ramos JT; Muñoz-Fernández MA
Pediatrics; 2003 Feb; 111(2):E168-75. PubMed ID: 12563091
[TBL] [Abstract][Full Text] [Related]
20. Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies.
Tate DF; Sampat M; Harezlak J; Fiecas M; Hogan J; Dewey J; McCaffrey D; Branson D; Russell T; Conley J; Taylor M; Schifitto G; Zhong J; Daar ES; Alger J; Brown M; Singer E; Campbell T; McMahon D; Tso Y; Matesan J; Letendre S; Paulose S; Gaugh M; Tripoli C; Yiannoutsos C; Bigler ED; Cohen RA; Guttmann CR; Navia B;
J Neurovirol; 2011 Aug; 17(4):368-79. PubMed ID: 21556960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
